PMC:7029759 / 920-1162 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"42","span":{"begin":55,"end":70},"obj":"Chemical"}],"attributes":[{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D009841"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"oping neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now,"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T22","span":{"begin":30,"end":38},"obj":"GO:0042571"},{"id":"T21","span":{"begin":94,"end":99},"obj":"NCBITaxon:10239"},{"id":"T20","span":{"begin":104,"end":110},"obj":"SO:0001026"}],"text":"oping neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now,"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":30,"end":38},"obj":"Body_part"},{"id":"T2","span":{"begin":100,"end":103},"obj":"Body_part"},{"id":"T3","span":{"begin":104,"end":110},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84116"}],"text":"oping neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now,"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":226,"end":227},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"oping neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now,"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T2","span":{"begin":55,"end":70},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_7754"}],"text":"oping neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now,"}